Xiaoping Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoping Zhang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Haiwei Li
Beijing Anzhen Hospital, Capital Medical University, China
5 shared publications- Yongquan Wu
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
5 shared publications Zefeng Wang
Beijing Anzhen Hospital, Capital Medical University, China
4 shared publicationsZhongyu Yuan
Beijing Anzhen Hospital, Capital Medical University China
4 shared publicationsChanghua Wang
1 Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
2 shared publicationsHuanfu Liu
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, 100029 Beijing, China
2 shared publications
Latest Publications
- Open Access
- 5 April 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 1-7
Safety and feasibility of carotid artery stenting using a 6F guiding catheter via right distal radial artery access
This study aimed to evaluate the safety and feasibility of carotid artery stenting (CAS) using a 6 F guiding catheter via right distal radial artery access. The clinical data of 32 patients who underwent internal carotid artery C1 stenting via right distal transradial artery access (rdTRA) at the Department of Cerebrovascular Diseases, Beijing Anzhen Hospital, between January 2022 and December 2023, were retrospectively analyzed. Parameters including puncture time, X-ray irradiation time, exposure dose, surgical success rate, surgery-related cardiovascular and cerebrovascular complications, puncture site complications, and postoperative radial artery patency were recorded and assessed. The procedural success rate of CAS through rdTRA was 100% (32/32). The time from operating room entry to successful puncture ranged from 3 to 36 min, with an average time of 18.56 ± 7.63 min. X-ray exposure time ranged from 12 to 27 min, with an average time of 19.18 ± 4.77 min. One patient experienced a procedure-related transient ischemic attack postoperatively, while another developed bruising along the radial artery course on the third postoperative day. During an out-of-hospital follow-up period averaging 1 to 29 months (median: 5.4 ± 3.6 months), no cardiovascular or cerebrovascular events were reported. The radial pulse was palpable in all patients postoperatively and during the follow-up, with radial artery patency confirmed through patency testing. Carotid artery stenting through rdTRA using a 6 F guiding catheter is a safe and feasible approach, demonstrating high procedural success and minimal complications.
- 5 April 2025
- Published by Springer Nature in BMC Neurology
- Vol. 25 (1) , 1-7
Open AccessSafety and feasibility of carotid artery stenting using a 6F guiding catheter via right distal radial artery access
This study aimed to evaluate the safety and feasibility of carotid artery stenting (CAS) using a 6 F guiding catheter via right distal radial artery access. The clinical data of 32 patients who underwent internal carotid artery C1 stenting via right distal transradial artery access (rdTRA) at the Department of Cerebrovascular Diseases, Beijing Anzhen Hospital, between January 2022 and December 2023, were retrospectively analyzed. Parameters including puncture time, X-ray irradiation time, exposure dose, surgical success rate, surgery-related cardiovascular and cerebrovascular complications, puncture site complications, and postoperative radial artery patency were recorded and assessed. The procedural success rate of CAS through rdTRA was 100% (32/32). The time from operating room entry to successful puncture ranged from 3 to 36 min, with an average time of 18.56 ± 7.63 min. X-ray exposure time ranged from 12 to 27 min, with an average time of 19.18 ± 4.77 min. One patient experienced a procedure-related transient ischemic attack postoperatively, while another developed bruising along the radial artery course on the third postoperative day. During an out-of-hospital follow-up period averaging 1 to 29 months (median: 5.4 ± 3.6 months), no cardiovascular or cerebrovascular events were reported. The radial pulse was palpable in all patients postoperatively and during the follow-up, with radial artery patency confirmed through patency testing. Carotid artery stenting through rdTRA using a 6 F guiding catheter is a safe and feasible approach, demonstrating high procedural success and minimal complications.
- Open Access
- 14 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26318
Clinical Utility of the 4S-AF Scheme in Predicting Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation
Background: The 4S-AF scheme, which comprises four domains related to atrial fibrillation (AF), stroke risk (St), symptom severity (Sy), severity of AF burden (Sb), and substrate (Su), represents a novel approach for structurally characterizing AF. This study aimed to assess the clinical utility of the scheme in predicting AF recurrence following radiofrequency catheter ablation (RFCA). Methods: We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds. Results: In total, 345 patients (age 61 (interquartile range (IQR): 53–68) years, 34.2% female, 70.7% paroxysmal AF) were analyzed. The median duration of AF history was 12 (IQR: 3–36) months, and the median number of comorbidities was 2 (IQR: 1–3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13–37) months, AF recurrence occurred in 34.4% of patients. After eliminating the Sy and St domains, both the 4S-AF scheme (hazard ratio (HR) 1.38, 95% confidence interval (CI): 1.19–1.59, p < 0.001) and severity of burden and substrate of atrial fibrillation (2S-AF) scheme scores (HR 1.59, 95% CI: 1.33–1.89, p < 0.001) were independent predictors of AF recurrence following RFCA. For each domain, we found that the independent predictors were Sb (HR 1.84, 95% CI: 1.25–2.72, p = 0.002) and Su (HR 1.71, 95% CI: 1.36–2.14, p < 0.001). Furthermore, the 4S-AF (area under the curve (AUC) 65.2%, 95% CI: 59.3–71.1) and 2S-AF scheme score (AUC 66.2%, 95% CI: 60.2–72.1) had a modest ability to predict AF recurrence after RFCA. Conclusions: The novel 4S-AF scheme is feasible for evaluating and characterizing AF patients who undergo RFCA. A higher 4S-AF scheme score is independently associated with AF recurrence after RFCA. However, the ability of the 4S-AF scheme to discriminate between patients at high risk of recurrence was limited.
- 14 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26318
Open AccessClinical Utility of the 4S-AF Scheme in Predicting Atrial Fibrillation Recurrence after Radiofrequency Catheter Ablation
Background: The 4S-AF scheme, which comprises four domains related to atrial fibrillation (AF), stroke risk (St), symptom severity (Sy), severity of AF burden (Sb), and substrate (Su), represents a novel approach for structurally characterizing AF. This study aimed to assess the clinical utility of the scheme in predicting AF recurrence following radiofrequency catheter ablation (RFCA). Methods: We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds. Results: In total, 345 patients (age 61 (interquartile range (IQR): 53–68) years, 34.2% female, 70.7% paroxysmal AF) were analyzed. The median duration of AF history was 12 (IQR: 3–36) months, and the median number of comorbidities was 2 (IQR: 1–3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13–37) months, AF recurrence occurred in 34.4% of patients. After eliminating the Sy and St domains, both the 4S-AF scheme (hazard ratio (HR) 1.38, 95% confidence interval (CI): 1.19–1.59, p < 0.001) and severity of burden and substrate of atrial fibrillation (2S-AF) scheme scores (HR 1.59, 95% CI: 1.33–1.89, p < 0.001) were independent predictors of AF recurrence following RFCA. For each domain, we found that the independent predictors were Sb (HR 1.84, 95% CI: 1.25–2.72, p = 0.002) and Su (HR 1.71, 95% CI: 1.36–2.14, p < 0.001). Furthermore, the 4S-AF (area under the curve (AUC) 65.2%, 95% CI: 59.3–71.1) and 2S-AF scheme score (AUC 66.2%, 95% CI: 60.2–72.1) had a modest ability to predict AF recurrence after RFCA. Conclusions: The novel 4S-AF scheme is feasible for evaluating and characterizing AF patients who undergo RFCA. A higher 4S-AF scheme score is independently associated with AF recurrence after RFCA. However, the ability of the 4S-AF scheme to discriminate between patients at high risk of recurrence was limited.
- Open Access
Clinical utility of the 4S-AF scheme in predicting recurrence of atrial fibrillation after radiofrequency catheter ablation
Background: The 4S-AF scheme, consisting of four domains related to atrial fibrillation (AF) [stroke risk (St), symptoms (Sy), severity of AF burden (Sb), and substrate (Su)], represents a novel approach for the structural characterization of AF. We aimed to assess the clinical utility of the scheme in predicting AF recurrence after radiofrequency catheter ablation (RFCA). Methods: We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds. Results: Of 345 patients [age 61 (IQR: 53-68) years, 34.2% female, 70.7% paroxysmal AF] were analyzed. The median duration of AF history was 12 (IQR: 3-36) months, and the median number of comorbidities was 2 (IQR: 1-3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13-37) months, AF recurrence occurred in 34.4% of patients. Both 4S-AF scheme score (HR 1.38, 95% CI: 1.19–1.59, P2 DS 2 -VASc score, 4S-AF scheme score and 2S-AF scheme score had better clinical predictive capability of AF recurrence.
Open AccessClinical utility of the 4S-AF scheme in predicting recurrence of atrial fibrillation after radiofrequency catheter ablation
Background: The 4S-AF scheme, consisting of four domains related to atrial fibrillation (AF) [stroke risk (St), symptoms (Sy), severity of AF burden (Sb), and substrate (Su)], represents a novel approach for the structural characterization of AF. We aimed to assess the clinical utility of the scheme in predicting AF recurrence after radiofrequency catheter ablation (RFCA). Methods: We prospectively enrolled 345 consecutive patients with AF who underwent initial RFCA between January 2019 and December 2019. The 4S-AF scheme score was calculated and used to characterize AF. The primary outcome assessed was AF recurrence after RFCA, defined as any documented atrial tachyarrhythmia episode lasting at least 30 seconds. Results: Of 345 patients [age 61 (IQR: 53-68) years, 34.2% female, 70.7% paroxysmal AF] were analyzed. The median duration of AF history was 12 (IQR: 3-36) months, and the median number of comorbidities was 2 (IQR: 1-3), and 157 (45.5%) patients had left atrial enlargement. During a median follow-up period of 28 (IQR: 13-37) months, AF recurrence occurred in 34.4% of patients. Both 4S-AF scheme score (HR 1.38, 95% CI: 1.19–1.59, P2 DS 2 -VASc score, 4S-AF scheme score and 2S-AF scheme score had better clinical predictive capability of AF recurrence.
- Open Access
- 5 April 2024
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 11, 1290574
Atrial lead perforation early after device implantation—a case report and literature review
We report three patients with screw-in lead perforation in the right atrial free wall not long after device implantation. All the patients complained of intermittent stabbing chest pain associated with deep breathing during the implantation. The “dry” epicardial puncture was utilized to avoid hemopericardium during lead extraction in the first case. The atrial electrode was repositioned in all cases and replaced by a new passive fixation lead in two patients with resolution of the pneumothorax or pericardial effusion. A literature review of 50 reported cases of atrial lead perforation was added to the findings in our case report.
- 5 April 2024
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 11, 1290574
Open AccessAtrial lead perforation early after device implantation—a case report and literature review
We report three patients with screw-in lead perforation in the right atrial free wall not long after device implantation. All the patients complained of intermittent stabbing chest pain associated with deep breathing during the implantation. The “dry” epicardial puncture was utilized to avoid hemopericardium during lead extraction in the first case. The atrial electrode was repositioned in all cases and replaced by a new passive fixation lead in two patients with resolution of the pneumothorax or pericardial effusion. A literature review of 50 reported cases of atrial lead perforation was added to the findings in our case report.
- Open Access
- 7 March 2024
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (3) , 96
Association between the Albumin-to-Globulin Ratio and Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy
Background: Atrial fibrillation (AF), which occurs four to six times more frequently in hypertrophic cardiomyopathy (HCM) patients than in the general population, is the most common persistent arrhythmia and has a substantial therapeutic consequence. In HCM patients, there are currently no discovered signs that could be utilized to identify AF. Methods: From 2018 to 2022, 493 individuals with a continuous diagnosis of HCM were examined at Beijing Anzhen Hospital. AF was proven using routine electrocardiography (ECG), 24-hour Holter ECGs, or bedside ECGs. Echocardiography and blood tests were performed for all patients. Analysis and comparison of the traits were performed in HCM patients with AF (n = 77) and without AF (n = 416). Results: Age (p <0.001), prevalence of ventricular tachycardia (VT, p < 0.001), prevalence of pulmonary artery hypertension (p = 0.027), and albumin-to-globulin ratio (AGR, p = 0.046) were all significantly higher in patients with AF, compared to patients without AF. In multivariate logistic analysis, age (odds ratio [OR], 1.063; 95% confidence interval [CI], 1.032–1.095; p < 0.001), history of VT (OR, 2.702; 95% CI, 1.007–7.255; p = 0.048), AGR (OR, 3.477; 95% CI, 1.417–8.536; p = 0.007), left atrial diameter (OR, 1.132; 95% CI, 1.073–1.194; p < 0.001), left ventricular end-diastolic diameter (OR, 0.861; 95% CI, 0.762–0.974; p = 0.017), left ventricular end-systolic diameter (OR, 1.239; 95% CI, 1.083–1.417; p = 0.002), and peak A wave velocity (OR, 0.983; 95% CI, 0.972–0.994; p = 0.002) were independently associated with AF in HCM patients. In the receiver operating characteristic curve analysis, the area under the curve for the established model was 0.819 (95% CI, 0.755–0.883, p = 0.033), with a sensitivity and specificity of 0.763 and 0.816, respectively, for AF occurrence in HCM patients. Conclusions: In individuals with HCM, a history of VT and a higher AGR are independently linked to AF. Further investigation is necessary to determine whether increased AGR represents a risk factor for embolic stroke or cardiovascular death.
- 7 March 2024
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (3) , 96
Open AccessAssociation between the Albumin-to-Globulin Ratio and Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy
Background: Atrial fibrillation (AF), which occurs four to six times more frequently in hypertrophic cardiomyopathy (HCM) patients than in the general population, is the most common persistent arrhythmia and has a substantial therapeutic consequence. In HCM patients, there are currently no discovered signs that could be utilized to identify AF. Methods: From 2018 to 2022, 493 individuals with a continuous diagnosis of HCM were examined at Beijing Anzhen Hospital. AF was proven using routine electrocardiography (ECG), 24-hour Holter ECGs, or bedside ECGs. Echocardiography and blood tests were performed for all patients. Analysis and comparison of the traits were performed in HCM patients with AF (n = 77) and without AF (n = 416). Results: Age (p <0.001), prevalence of ventricular tachycardia (VT, p < 0.001), prevalence of pulmonary artery hypertension (p = 0.027), and albumin-to-globulin ratio (AGR, p = 0.046) were all significantly higher in patients with AF, compared to patients without AF. In multivariate logistic analysis, age (odds ratio [OR], 1.063; 95% confidence interval [CI], 1.032–1.095; p < 0.001), history of VT (OR, 2.702; 95% CI, 1.007–7.255; p = 0.048), AGR (OR, 3.477; 95% CI, 1.417–8.536; p = 0.007), left atrial diameter (OR, 1.132; 95% CI, 1.073–1.194; p < 0.001), left ventricular end-diastolic diameter (OR, 0.861; 95% CI, 0.762–0.974; p = 0.017), left ventricular end-systolic diameter (OR, 1.239; 95% CI, 1.083–1.417; p = 0.002), and peak A wave velocity (OR, 0.983; 95% CI, 0.972–0.994; p = 0.002) were independently associated with AF in HCM patients. In the receiver operating characteristic curve analysis, the area under the curve for the established model was 0.819 (95% CI, 0.755–0.883, p = 0.033), with a sensitivity and specificity of 0.763 and 0.816, respectively, for AF occurrence in HCM patients. Conclusions: In individuals with HCM, a history of VT and a higher AGR are independently linked to AF. Further investigation is necessary to determine whether increased AGR represents a risk factor for embolic stroke or cardiovascular death.
- Open Access
- 16 December 2022
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 22 (1) , 1-7
Sex differences involved in persistent atrial fibrillation recurrence after radiofrequency ablation
In recent years, the difference in outcomes of radiofrequency catheter ablation (RFCA) in persistent atrial fibrillation patients has risen. In particular, biological sex seems involved in a different response to the AF ablation procedure. In our study, we analyzed the AF recurrences after RFCA assessing the other association between male/female patients with the outcomes. We enrolled 106 patients (74.5% men) with persistent atrial fibrillation with scheduled follow-up. The baseline clinical characteristics and AF recurrence after RFCA were compared between men and women. Cox regression analyses were performed to determine the risk predictors of AF recurrence. The proportion of RFCA in women was lower than that in men. Men with persistent AF were younger than women (58.6 ± 10.4 years vs. 65.1 ± 8.7 years, respectively; p = 0.003). The left atrium (LA) diameter was higher in males (43.7 ± 4.6 mm vs. 41.3 ± 5.5 mm; p = 0.028), and the level of left heart ejection fraction (LVEF) was higher in females (59.4 ± 6.9% vs. 64.1 ± 5.5%; p = 0.001). Sex differences in AF recurrence after RFCA were significant during the median 24.4-month (interquartile range: 15.2–30.6 months) follow-up period, and the recurrence rate of AF in women was significantly higher than that in men (p = 0.005). Univariable Cox regression analysis showed that female sex was a risk factor for persistent AF recurrence after RFCA [HR: 2.099 (1.087–4.053)]. Univariate Cox regression analysis revealed that non-PV ablation not associated with AF recurrence [HR: 1.003 (0.516–1.947)]. In a monocentric cohort of persistent AF patients, the female biological sex was associated with a higher risk of AF recurrence after RFCA.
- 16 December 2022
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 22 (1) , 1-7
Open AccessSex differences involved in persistent atrial fibrillation recurrence after radiofrequency ablation
In recent years, the difference in outcomes of radiofrequency catheter ablation (RFCA) in persistent atrial fibrillation patients has risen. In particular, biological sex seems involved in a different response to the AF ablation procedure. In our study, we analyzed the AF recurrences after RFCA assessing the other association between male/female patients with the outcomes. We enrolled 106 patients (74.5% men) with persistent atrial fibrillation with scheduled follow-up. The baseline clinical characteristics and AF recurrence after RFCA were compared between men and women. Cox regression analyses were performed to determine the risk predictors of AF recurrence. The proportion of RFCA in women was lower than that in men. Men with persistent AF were younger than women (58.6 ± 10.4 years vs. 65.1 ± 8.7 years, respectively; p = 0.003). The left atrium (LA) diameter was higher in males (43.7 ± 4.6 mm vs. 41.3 ± 5.5 mm; p = 0.028), and the level of left heart ejection fraction (LVEF) was higher in females (59.4 ± 6.9% vs. 64.1 ± 5.5%; p = 0.001). Sex differences in AF recurrence after RFCA were significant during the median 24.4-month (interquartile range: 15.2–30.6 months) follow-up period, and the recurrence rate of AF in women was significantly higher than that in men (p = 0.005). Univariable Cox regression analysis showed that female sex was a risk factor for persistent AF recurrence after RFCA [HR: 2.099 (1.087–4.053)]. Univariate Cox regression analysis revealed that non-PV ablation not associated with AF recurrence [HR: 1.003 (0.516–1.947)]. In a monocentric cohort of persistent AF patients, the female biological sex was associated with a higher risk of AF recurrence after RFCA.
- Open Access
- 13 October 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 961914
Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation
Background: Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels is strongly associated with cardiac extracellular matrix accumulation and atrial fibrosis. Whether serum levels of TIMP-1 are associated with atrial fibrillation (AF) recurrence following radiofrequency catheter ablation (RFCA) remains unknown.Materials and methods: Serum TIMP-1 levels of patients with AF before they underwent initial RFCA were measured using ELISA. Univariate and multivariate-adjusted Cox models were constructed to determine the relationship between TIMP-1 levels and AF recurrence. Multivariate logistic regression analyses were performed to determine predictors of AF recurrence.Results: Of the 194 enrolled patients, 61 (31.4%) had AF recurrence within the median 30.0 months (interquartile range: 16.5–33.7 months) of follow-up. These patients had significantly higher baseline TIMP-1 levels than those without AF recurrence (129.8 ± 65.7 vs. 112.0 ± 51.0 ng/ml, P = 0.041). The same was true of high-sensitivity C-reactive protein (3.9 ± 6.0 vs. 1.9 ± 2.8 ng/ml, P = 0.001). When a TIMP-1 cutoff of 124.15 ng/ml was set, patients with TIMP-1 ≥ 124.15 ng/ml had a higher risk of recurrent AF than those with TIMP-1 < 124.15 ng/ml (HR, 1.961, 95% CI, 1.182–2. 253, P = 0.009). Multivariate Cox regression analysis revealed that high TIMP-1 was an independent risk factor for AF recurrence. Univariate Cox regression analysis found that substrate modification surgery does not affect AF recurrence (P = 0.553). Subgroup analysis revealed that female sex, age < 65 years, hypertension (HTN), body mass index (BMI) ≥ 24 kg/m2, CHA2DS2-VASc score < 2, HAS-BLED score < 3, and EHRA score = 3 combined with high TIMP-1 level would perform well at predicting AF recurrence after RFCA.Conclusion: Elevated preoperative TIMP-1 levels are related to a higher risk of AF recurrence and can independently predict AF recurrence following RFCA.
- 13 October 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 961914
Open AccessHigher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation
Background: Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels is strongly associated with cardiac extracellular matrix accumulation and atrial fibrosis. Whether serum levels of TIMP-1 are associated with atrial fibrillation (AF) recurrence following radiofrequency catheter ablation (RFCA) remains unknown.Materials and methods: Serum TIMP-1 levels of patients with AF before they underwent initial RFCA were measured using ELISA. Univariate and multivariate-adjusted Cox models were constructed to determine the relationship between TIMP-1 levels and AF recurrence. Multivariate logistic regression analyses were performed to determine predictors of AF recurrence.Results: Of the 194 enrolled patients, 61 (31.4%) had AF recurrence within the median 30.0 months (interquartile range: 16.5–33.7 months) of follow-up. These patients had significantly higher baseline TIMP-1 levels than those without AF recurrence (129.8 ± 65.7 vs. 112.0 ± 51.0 ng/ml, P = 0.041). The same was true of high-sensitivity C-reactive protein (3.9 ± 6.0 vs. 1.9 ± 2.8 ng/ml, P = 0.001). When a TIMP-1 cutoff of 124.15 ng/ml was set, patients with TIMP-1 ≥ 124.15 ng/ml had a higher risk of recurrent AF than those with TIMP-1 < 124.15 ng/ml (HR, 1.961, 95% CI, 1.182–2. 253, P = 0.009). Multivariate Cox regression analysis revealed that high TIMP-1 was an independent risk factor for AF recurrence. Univariate Cox regression analysis found that substrate modification surgery does not affect AF recurrence (P = 0.553). Subgroup analysis revealed that female sex, age < 65 years, hypertension (HTN), body mass index (BMI) ≥ 24 kg/m2, CHA2DS2-VASc score < 2, HAS-BLED score < 3, and EHRA score = 3 combined with high TIMP-1 level would perform well at predicting AF recurrence after RFCA.Conclusion: Elevated preoperative TIMP-1 levels are related to a higher risk of AF recurrence and can independently predict AF recurrence following RFCA.